Migraine and neuropathic pain (NP) are both painful, disabling, chronic conditions which
exhibit some symptom similarities and are thus considered to share a common etiology. The …

Since its initial approval in 1989 by the US Food and Drug Administration for the treatment of
blepharospasm and other facial spasms, botulinum toxin (BoNT) has evolved into a …

This study assessed the safety and efficacy of three different doses of BoNT-A for persistent
myofascial pain (MFP). One hundred female subjects were randomly assigned into five …

The antinociceptive effect of BoNT-A have been well documented in animal studies;
however, results of few but well-designed randomized placebo-controlled clinical trials …

Neurotoxins generally inhibit or promote the release of neurotransmitters or bind to
receptors that are located in the pre-or post-synaptic membranes, thereby affecting …

Objectives: Cumulative evidence support a beneficial effect of botulinum toxin A (BTX-A) in
postherpetic neuralgia (PHN). We aimed to assess efficacy, safety, and tolerability of BTX-A …

This study assessed the long-term effects of botulinum toxin type A (BoNT-A) in subjective
pain, pain sensibility, and muscle thickness in persistent myofascial temporomandibular …

Botulinum toxin type A (BTA) injection is considered an available alternative treatment for
myofascial pain. However, its efficacy in treating masticatory myofascial pain syndrome …

Trigeminal neuralgia (TN), the most common form of severe facial pain, may be confused
with an ill-defined persistent idiopathic facial pain (PIFP). Facial pain is reviewed and a …

CONCLUSIONS A beneficial effect on spasticity was found for both treatments: evidence
showed that ESWT and BoNT-A can ameliorate spasticity considering parameters such as …